Skip to main content
SpringerLink
Log in

Amyloidosis

  • Chapter
  • First Online:
Neurorheumatology

  • 965 Accesses

Abstract

Amyloidosis refers to a group of hereditary and acquired disorders characterized by accumulation and extracellular deposition of insoluble higher-order oligomers of misfolded proteins in a beta-pleated sheet configuration that specifically bind with Congo red dye and demonstrate green, yellow, or orange birefringence under polarized microscopy. These deposits are found in central and peripheral nervous system in addition to kidneys, heart, liver, skin, musculoskeletal system, lungs, cornea, etc. There are currently 36 different amyloid fibrils identified in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Amato AA, Russell JA. Neuromuscular disorders. New York/London: McGraw-Hill Medical; 2008.

    Google Scholar 

  2. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 19th ed. New York: McGraw Hill Education; 2015.

    Google Scholar 

  3. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209–13.

    Article  CAS  PubMed  Google Scholar 

  4. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96.

    Article  CAS  PubMed  Google Scholar 

  5. Wang AK, Fealey RD, Gehrking TL, Low PA. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc. 2008;83(11):1226–30.

    Article  PubMed  Google Scholar 

  6. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–27.

    Article  CAS  PubMed  Google Scholar 

  7. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086–97.

    Article  CAS  PubMed  Google Scholar 

  8. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994;31(5):351–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Morrow JM, Reilly MM. Early detection of nerve injury in transthyretin-related familial amyloid polyneuropathy. Brain. 2015;138(Pt 3):507–9.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sasaki H, Yoshioka N, Takagi Y, Sakaki Y. Structure of the chromosomal gene for human serum prealbumin. Gene. 1985;37(1–3):191–7.

    CAS  PubMed  Google Scholar 

  12. Koike H, Morozumi S, Kawagashira Y, Iijima M, Yamamoto M, Hattori N, et al. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid. 2009;16(3):142–8.

    Article  CAS  PubMed  Google Scholar 

  13. Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116–8.

    Article  CAS  PubMed  Google Scholar 

  15. Plante-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693–8.

    Article  CAS  PubMed  Google Scholar 

  16. Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11(3):257–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733–48.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Maury CP. Immunohistochemical localization of amyloid in Finnish hereditary amyloidosis with antibodies to gelsolin peptides. Lab Investig. 1991;64(3):400–4.

    CAS  PubMed  Google Scholar 

  19. Tanskanen M, Paetau A, Salonen O, Salmi T, Lamminen A, Lindsberg P, et al. Severe ataxia with neuropathy in hereditary gelsolin amyloidosis: a case report. Amyloid. 2007;14(1):89–95.

    Article  PubMed  Google Scholar 

  20. Chastan N, Baert-Desurmont S, Saugier-Veber P, Derumeaux G, Cabot A, Frebourg T, et al. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the GSN gene. Muscle Nerve. 2006;33(1):113–9.

    Article  CAS  PubMed  Google Scholar 

  21. Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis. 2010;11(3):145–57.

    Article  PubMed  Google Scholar 

  22. Li K, Kyle RA, Dyck PJ. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol. 1992;141(1):217–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Klein CJ, Vrana JA, Theis JD, Dyck PJ, Spinner RJ, Mauermann ML, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195–9.

    Article  PubMed  Google Scholar 

  24. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–43.

    Article  PubMed  Google Scholar 

  25. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl. 2009;15(10):1229–35.

    Article  PubMed  Google Scholar 

  26. Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597–604.

    Article  CAS  PubMed  Google Scholar 

  27. Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalarrondo V, Theaudin M. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother. 2016;17(6):791–802.

    Article  CAS  PubMed  Google Scholar 

  28. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Testro AG, Brennan SO, Macdonell RA, Hawkins PN, Angus PW. Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl. 2007;13(7):1028–31.

    Article  PubMed  Google Scholar 

  31. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998;104(3):232–7.

    Article  CAS  PubMed  Google Scholar 

  32. Mauermann ML. Paraproteinemic neuropathies. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1307–22.

    Google Scholar 

  33. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999 Dec;13(6):1211–33, ix.

    Google Scholar 

  34. Kelly JJ Jr, Kyle RA, O’Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979;6(1):1–7.

    Article  PubMed  Google Scholar 

  35. Adams D, Lozeron P, Theaudin M, Denier C, Fagniez O, Rerat K, et al. Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid. 2011;18(Suppl 1):98–100.

    Article  PubMed  Google Scholar 

  36. Luigetti M, Papacci M, Bartoletti S, Marcaccio A, Romano A, Sabatelli M. AL amyloid neuropathy mimicking a chronic inflammatory demyelinating polyneuropathy. Amyloid. 2012;19(1):53–5.

    Article  PubMed  Google Scholar 

  37. Tracy JA, Dyck PJ. Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve. 2010;41(5):710–5.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol. 2011;18(4):604–10.

    Article  CAS  PubMed  Google Scholar 

  39. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91(9):947–56.

    Article  CAS  PubMed  Google Scholar 

  40. Blancas-Mejia LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem. 2013;82:745–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tsunoda I, Awano H, Kayama H, Tsukamoto T, Ueno S, Fujiwara T, et al. Idiopathic AA amyloidosis manifested by autonomic neuropathy, vestibulocochleopathy, and lattice corneal dystrophy. J Neurol Neurosurg Psychiatry. 1994;57(5):635–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Perez-de la Fuente T, Fernandez-Jara J, Rodriguez-Urcelay P, Jimenez-Heffernan J, Juarez A. Isolated AA amyloidosis of the radial nerve. Hand (N Y). 2017;12(5):NP136–NP9.

    Article  Google Scholar 

  43. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol. 2010;6(7):417–29.

    Article  CAS  PubMed  Google Scholar 

  44. Valleix S, Gillmore JD, Bridoux F, Mangione PP, Dogan A, Nedelec B, et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin. N Engl J Med. 2012;366(24):2276–83.

    Article  CAS  PubMed  Google Scholar 

  45. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.

    Article  Google Scholar 

  46. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–27.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42(3 Pt 1):631–9.

    Article  CAS  PubMed  Google Scholar 

  49. Apostolova LG. Alzheimer Disease. Continuum (Minneap Minn). 2016;22(2 Dementia):419–34.

    PubMed  PubMed Central  Google Scholar 

  50. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;10(6):CD008782.

    Google Scholar 

  52. Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC. Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3:CD010803.

    PubMed  Google Scholar 

  53. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317–24.

    CAS  PubMed  Google Scholar 

  54. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97.

    Article  PubMed  Google Scholar 

  55. Deardorff WJ, Grossberg GT. Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease. Expert Opin Pharmacother. 2016;17(13):1789–800.

    Article  CAS  PubMed  Google Scholar 

  56. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–31.

    Article  PubMed  Google Scholar 

  57. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2):311–24.

    Article  CAS  PubMed  Google Scholar 

  58. Keage HA, Carare RO, Friedland RP, Ince PG, Love S, Nicoll JA, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9:3.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S115–23.

    Article  PubMed  Google Scholar 

  60. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke. 1997;28(7):1418–22.

    Article  CAS  PubMed  Google Scholar 

  61. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83(2):124–37.

    Article  PubMed  Google Scholar 

  62. Schneider JA. The cerebral cortex in cerebral amyloid angiopathy. Lancet Neurol. 2016;15(8):778–9.

    Article  PubMed  Google Scholar 

  63. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke. 2009;40(7):2601–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry. 2011;82(1):20–6.

    Article  PubMed  Google Scholar 

  65. Ding J, Sigurethsson S, Jonsson PV, Eiriksdottir G, Meirelles O, Kjartansson O, et al. Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology. 2017;88(22):2089–97.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Chung CP, Chou KH, Chen WT, Liu LK, Lee WJ, Chen LK, et al. Strictly lobar cerebral microbleeds are associated with cognitive impairment. Stroke. 2016;47(10):2497–502.

    Article  PubMed  Google Scholar 

  67. Charidimou A, Peeters A, Fox Z, Gregoire SM, Vandermeeren Y, Laloux P, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke. 2012;43(9):2324–30.

    Article  PubMed  Google Scholar 

  68. Salvarani C, Hunder GG, Morris JM, Brown RD Jr, Christianson T, Giannini C. Abeta-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis. Neurology. 2013;81(18):1596–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56(4):537–9.

    Article  CAS  PubMed  Google Scholar 

  70. Martucci M, Sarria S, Toledo M, Coscojuela P, Vert C, Siurana S, et al. Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical outcome. Neuroradiology. 2014;56(4):283–9.

    Article  PubMed  Google Scholar 

  71. Salvarani C, Morris JM, Giannini C, Brown RD Jr, Christianson T, Hunder GG. Imaging Findings of Cerebral Amyloid Angiopathy, Aβ-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy-Related Inflammation: A Single-Institution 25-Year Experience. Medicine (Baltimore). 2016;95(20):e3613.

    Article  CAS  Google Scholar 

  72. Charidimou A, Martinez-Ramirez S, Reijmer YD, Oliveira-Filho J, Lauer A, Roongpiboonsopit D, et al. Total magnetic resonance imaging burden of small vessel disease in cerebral amyloid angiopathy: an imaging-pathologic study of concept validation. JAMA Neurol. 2016;73(8):994–1001.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Charidimou A, Jager RH, Fox Z, Peeters A, Vandermeeren Y, Laloux P, et al. Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology. 2013;81(7):626–32.

    Article  PubMed  Google Scholar 

  74. Charidimou A, Jaunmuktane Z, Baron JC, Burnell M, Varlet P, Peeters A, et al. White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology. 2014;82(1):57–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Chao CP, Kotsenas AL, Broderick DF. Cerebral amyloid angiopathy: CT and MR imaging findings. Radiographics. 2006;26(5):1517–31.

    Article  PubMed  Google Scholar 

  76. Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 2016;73(2):197–202.

    Article  PubMed  Google Scholar 

  77. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66(2):245–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer’s disease. Clin Chem Lab Med. 2007;45(11):1421–34.

    PubMed  Google Scholar 

  79. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. 2007;68(17):1411–6.

    Article  CAS  PubMed  Google Scholar 

  80. Kimura A, Sakurai T, Yoshikura N, Hayashi Y, Takemura M, Takahashi H, et al. Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation. J Neuroinflammation. 2013;10:39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Kloppenborg RP, Richard E, Sprengers ME, Troost D, Eikelenboom P, Nederkoorn PJ. Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. J Neuroinflammation. 2010;7:18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Mandybur TI, Balko G. Cerebral amyloid angiopathy with granulomatous angiitis ameliorated by steroid-cytoxan treatment. Clin Neuropharmacol. 1992;15(3):241–7.

    Article  CAS  PubMed  Google Scholar 

  83. Dohrn MF, Rocken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol. 2013;260(12):3093–108.

    Article  CAS  PubMed  Google Scholar 

  84. Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457–8.

    Article  PubMed  Google Scholar 

  85. Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2012;45(1):26–31.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Lahey Hospital & Medical Center, Tufts University School of Medicine, Burlington, MA, USA

    Pooja Raibagkar

  2. Division of Neuroimmunology and Neuroinfectious Diseases, Advanced General and Autoimmune Neurology, Massachusetts General Hospital, Boston, MA, USA

    Nagagopal Venna

Authors
  1. Pooja Raibagkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nagagopal Venna
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neuroimmunology, University of Iowa, Iowa City, IA, USA

    Tracey A. Cho

  2. Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Shamik Bhattacharyya

  3. Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Simon Helfgott

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Raibagkar, P., Venna, N. (2019). Amyloidosis. In: Cho, T., Bhattacharyya, S., Helfgott, S. (eds) Neurorheumatology. Springer, Cham. https://doi.org/10.1007/978-3-030-16928-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16928-2_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16927-5

  • Online ISBN: 978-3-030-16928-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation